The article, written in collaboration with the patient advocacy group Together Against Diabetes 1 (T.A.D.1), recounts Hugo and his family's journey since his diagnosis in October 2024 and their experience participating in the clinical trial. Although the family does not know whether Hugo received ProTrans or placebo, they describe a life change for the better, with stable blood sugar levels, reduced anxiety, and significantly fewer night time alarms.

"We even have 24-hour periods without a single alarm," Hugo's mother Anna shares in the article.

ProTrans is an allogeneic cell therapy based on mesenchymal stromal cells derived from umbilical cord tissue and administered as a single intravenous infusion. The goal is to halt disease progression and preserve the patient's endogenous insulin production. Previous clinical trials in adults have demonstrated that patients receiving ProTrans maintain significantly higher levels of insulin production compared to placebo, with effects lasting for at least five years.

The ongoing paediatric trial, ProTrans-Young, is sponsored by Uppsala University with Professor Per-Ola Carlsson as the principal investigator. For more information (in Swedish), please visit: nextcellpharma.com/studie

The article is attached to this press release and is also available in full at nextcellpharma.com, SvD Vårdfokus Diabetes. The space in the newspaper supplement was funded by NextCell, but the content was produced by an independent writer in collaboration with T.A.D.1.